Aptargroup, Inc. · NYSE:ATR
Aptargroup — Q4 2025 Earnings Presentation
29 slides from Aptargroup's earnings presentation, Feb 6, 2026
Slide 1: Q4 and Full Year 2025 Results
February 6, 2026 Q4 and Full Year 2025 Results Stephan B. Tanda, Aptar President and CEO Vanessa Kanu, Executive Vice President and CFO
Slide 2: Forward Looking Statements & Non-GAAP Financial Measures
Forward Looking Statements & Non-GAAP Financial Measures This presentation includes forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based
Slide 3: 2025 Financial Highlights
2025 Financial Highlights Fourth Quarter 2025 Highlights: 2025 % of Total Reported Sales • Reported sales increased 14% and core sales increased 5%—all three segments Beverage delivered core sales growth 5% Food • Reported net income decreased 26% to $74 million and reported earnings per share 10% P
Slide 4: Recent Product and Technology Highlights
Recent Product and Technology Highlights Pharma Beauty Closures Bidose Nasal LuerVax® and Beat the Blink Airless Pump and Flip Top Tamper PCR High-Dosage, All Custom Premium Reloadable System with Dual Spray Divider for Eyecare Technology Pour Evident Sports Dosing Plastic Pump Airless Pump Technolo
Slide 5: Recent Recognitions
Recent Recognitions Our award-winning commitment to sustainability is a competitive advantage that drives impact for our customers CDP Newsweek Forbes TIME CDP EcoVadis Barron’s* ISS ESG USA Today Le Point Climate A In the Top 100 One of the One of the Recognized as a Sustainability Rating In the To
Slide 6: Fourth Quarter 2025 Reported Results
Fourth Quarter 2025 Reported Results Q4 Reported Sales Q4 Reported EPS (in millions $) $1,200 $1.60 $1.49 $963 $1.40 -24% $1,000 $848 14% $1.13 $1.20 $800 $1.00 $600 $0.80 $0.60 $400 $0.40 $200 $0.20 $- $- Q4 2024 Q4 2025 Q4 2024 Q4 2025 +6% 13.1% 18.9% +5% Currency Effects Q4 2024 Q4 2025 Core Sale
Slide 7: Fourth Quarter 2025 Adj. EPS and Adj. EBITDA
Fourth Quarter 2025 Adj. EPS and Adj. EBITDA Q4 Adjusted EPS * Q4 Adjusted EBITDA* (in millions $) $2.00 $280 $1.80 $1.62 $240 $1.60 -23% $1.40 $200 $195 -2% $191 $1.25 $1.20 $160 $1.00 $0.80 $120 $0.60 $80 $0.40 $0.20 $40 $- $- Q4 2024 Q4 2025 Q4 2024 Q4 2025 13.5% 19.4% Q4 2024 Q4 2025 Effective T
Slide 8: Pharma Fourth Quarter 2025 Results
Pharma Fourth Quarter 2025 Results Q4 2025 Core Sales* by Market Q4 Sales (in millions $) Adjusted EBITDA Margin % $500 40% 35.7% • Prescription core sales increased 1% $450 $440 $401 32.4% • Consumer Healthcare core sales increased $400 3% Reported 30% $350 10% • Injectables core sales increased 24
Slide 9: Beauty Fourth Quarter 2025 Results
Beauty Fourth Quarter 2025 Results Q4 Sales (in millions $) Adjusted EBITDA Margin % Q4 2025 Core Sales* by Market $360 $341 16% $320 • Fragrance, Facial Skincare and 14% Color Cosmetics (F&F) core sales $274 12.4% $280 increased 7% Reported 12% $240 24% 10.2% • Personal Care core sales increased 10
Slide 10: Closures Fourth Quarter 2025 Results
Closures Fourth Quarter 2025 Results Q4 Sales Adjusted EBITDA Margin % Q4 2025 Core Sales* by Market (in millions $) $200 18% $182 16.1% • Food core sales decreased 1% $180 $173 16% 14.9% • Beverage core sales increased 7% $160 Reported 14% $140 5% • Personal Care core sales decreased 8% 12% $120 Co
Slide 11: Full Year 2025 Reported Results
Full Year 2025 Reported Results FY Reported Sales $4,500 (in millions $) FY Reported EPS $7.00 $4,000 $3,777 $3,583 5% $5.89 $3,500 $6.00 $5.53 7% $3,000 $5.00 $2,500 $4.00 $2,000 $3.00 $1,500 $2.00 $1,000 $1.00 $500 $- $- FY 2024 FY 2025 FY 2024 FY 2025 +2% 20.3% 20.1% +2% Currency Effects FY 2024
Slide 12: Full Year 2025 Adj. EPS, Adj. EBITDA and Free Cash Flow
Full Year 2025 Adj. EPS, Adj. EBITDA and Free Cash Flow FY Adjusted EPS* FY Adjusted FY Adjusted EBIDTA EBITDA Free Cash Flow* (in millions $) $7.00 $1,000 $5.81 -1% $5.74 $900 • Free cash flow was $6.00 5% $815 $800 $775 $303 million comprising $5.00 $700 cash from operations of $4.00 $600 $570 mil
Slide 13: Outlook
Outlook Earnings Per Share Outlook Highlights $1.80 • Looking ahead to the first quarter and 2026, we expect $1.60 strong growth within Pharma outside of emergency $1.40 $1.30 medicine, which is going through a period of destocking $1.17 $1.13 – $1.21 $1.20 $1.00 • Injectables, systemic nasal drug d
Slide 14: Key Highlights for Q1/FY2026
Key Highlights for Q1/FY2026 Quarterly Effective Tax Rate 21 to 23% for Q1 2026 Prior year Q1 comparable adjusted effective tax rate = 13.5% Currency Guidance (Euro) 1.18 for Q1 2026 Assuming a Euro to USD Exchange Rate Full Year CapEx Range for Full Year 2026 $260 to $280 million Net of any governm
Slide 15: Appendix
Aptar.4 Appendix
Slide 16: Adjusted EBIT and Adjusted EBITDA to Net Income
Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited) ($ In Thousands) 16
Slide 17: Adjusted EBIT and Adjusted EBITDA to Net Income
Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited) ($ In Thousands) 17
Slide 18: Adjusted Earnings Per Diluted Share
Reconciliation of Adjusted Earnings Per Diluted Share (Unaudited) ($ In Thousands Except Per Share Data) 18
Slide 19: Adjusted Earnings Per Diluted Share
Reconciliation of Adjusted Earnings Per Diluted Share (Unaudited) ($ In Thousands Except Per Share Data) 19
Slide 20: Reconciliation of Reported to Core Sales Growth
Fourth Quarter 2025 Reconciliation of Reported to Core Sales Growth Reconciliation (rounded to the nearest whole percent) of Reported to Active Core Sales Material Growth by Fourth Quarter Segment Sales Analysis Prescription Consumer Science Total Market (Change over Prior Year) Drug (2) Health Care
Slide 21: Adjusted EBIT and Adjusted EBITDA to Net Income
Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited) ($ In Thousands) 21
Slide 22: Adjusted EBIT and Adjusted EBITDA to Net Income
Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited) ($ In Thousands) 22
Slide 23: Adjusted Earnings Per Diluted Share
Reconciliation of Adjusted Earnings Per Diluted Share (Unaudited) ($ In Thousands, Except Per Share Data) 23
Slide 24: Adjusted EBIT After Taxes to Net Income
Reconciliation of Adjusted EBIT After Taxes to Net Income (Unaudited) ($ In Thousands) 24
Slide 25: Capital to Stockholders' Equity
Reconciliation of Capital to Stockholders’ Equity (Unaudited) ($ In Thousands) 25
Slide 26: Free Cash Flow to Net Cash Provided by Operations
Reconciliation of Free Cash Flow to Net Cash Provided by Operations (Unaudited) ($ In Thousands) 26
Slide 27: Free Cash Flow to Net Cash Provided by Operations
Reconciliation of Free Cash Flow to Net Cash Provided by Operations (Unaudited) Fourth Quarter Full Year ($ In Thousands) 2025 2024 2025 2024 Net Cash Provided by Operations 183,693 178,239 569,999 643,413 Capital Expenditures (86,819) (66,065) (270,419) (276,481) Proceeds from Government Grants - -
Slide 28: Supplemental Information
Supplemental Information 28
Slide 29: Follow us on:
265 Exchange Drive Suite 301 Crystal Lake, IL 60014 +1-815-477-0424 Aptar.com Follow us on: 29